PolyPeptide Group AG (SWX:PPGN)

Market Cap	1.45B +72.9%
Revenue (ttm)	423.58M +24.4%
Net Income	13.34M
EPS	0.41
Shares Out	33.02M
PE Ratio	107.73
Forward PE	38.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,941
Open	44.05
Previous Close	44.00
Day's Range	44.00 - 44.05
52-Week Range	21.80 - 50.10
Beta	1.00
Analysts	Hold
Price Target	39.77 (-9.72%)
Earnings Date	Mar 9, 2027

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1952
• Employees: 1,460
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: PPGN

Financial Performance

In 2025, PolyPeptide Group AG's revenue was 389.33 million, an increase of 15.60% compared to the previous year's 336.79 million. Losses were -21.17 million, 8.20% more than in 2024.

Financial numbers in EUR

Analyst Summary

According to 5 analysts, the average rating for PPGN stock is "Hold." The 12-month stock price target is CHF 39.77, which is a decrease of -9.72% from the latest price.

Price Target

CHF 39.77

(-9.72% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error